---
title: "Cell Source 10‑K: $4.51M Net Loss, Cash $0.075M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281862356.md"
description: "Cell Source reported a net loss of $4.513 million for the year ended December 31, 2024, with cash reserves of only $0.075 million and a working capital deficiency of $(18.538) million. The loss was attributed to increased R&D spending of $1.898 million and general administrative expenses of $1.942 million. The company is advancing clinical programs while operating with a lean staff, primarily using contractors. Key highlights include progress in clinical trials and a strategic focus on expanding product opportunities in CAR-T therapies and organ transplants."
datetime: "2026-04-07T10:05:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281862356.md)
  - [en](https://longbridge.com/en/news/281862356.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281862356.md)
---

# Cell Source 10‑K: $4.51M Net Loss, Cash $0.075M

Cell Source reported a net loss of $4.513 million for the year ended December 31, 2024, with minimal cash on hand of $0.075 million and a significant working capital deficiency, reflecting continued investment in research and development and limited operating liquidity. Earnings per share and revenue figures were not disclosed in the filing; the loss was driven in part by increased R&D spending and ongoing general and administrative expenses. The company is advancing clinical and preclinical programs while operating with a lean staff and contractor model.

**Financial Highlights**

-   **Net Loss**: $4.513 million for the year ended Dec 31, 2024.
-   **Research and Development**: $1.898 million (20% increase versus 2023; increase driven by patient enrollment milestones).
-   **General and Administrative**: $1.942 million (25% decrease versus 2023; lower legal, stock‑based compensation, and consulting costs).
-   **Cash**: $0.075 million as of Dec 31, 2024.
-   **Working Capital Deficiency**: $(18.538) million.
-   **Accumulated Deficit**: $46.180 million.

**Business Highlights**

-   **Clinical Progress**: Completed five cohorts of the Phase 1/2 MD Anderson trial with 15 patients per cohort; Veto Cells demonstrated engraftment and no severe graft‑versus‑host disease (GvHD).
-   **R&D Focus Shift**: Research activities have been centralized at MD Anderson, with plans to submit a VETO CAR‑T protocol in 2025.
-   **Preclinical Validation**: Data indicate Veto Cells extend persistence of genetically modified T cells and help overcome NK/T cell‑mediated rejection.
-   **Product Opportunity Expansion**: Strategic focus broadened to target allogeneic CAR‑T, solid tumors, organ transplants, and non‑malignant hematologic diseases.
-   **Operational Staffing**: Company maintains a minimal headcount—CEO is the only full‑time employee—with operations supported primarily by contractors and consultants.

Original SEC Filing: Cell Source, Inc. \[ CLCS \] - 10-K - Apr. 06, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [CELT.US](https://longbridge.com/en/quote/CELT.US.md)
- [LCTX.US](https://longbridge.com/en/quote/LCTX.US.md)

## Related News & Research

- [Noveris Health Sciences Provides Corporate Update, and Announces Agreement for Acquisition of Stem Cell Distribution Business](https://longbridge.com/en/news/284610272.md)
- [A Look Ahead: Lineage Cell Therapeutics's Earnings Forecast](https://longbridge.com/en/news/277818131.md)
- [06:21 ETCellenkos, Inc. Announces FDA Clearance to Initiate Phase 2 Clinical Trial of CK0801 (Allogeneic Cord Blood-Derived Tregs) for Aplastic Anemia](https://longbridge.com/en/news/284195057.md)
- [Bloom Energy’s big day propels fellow fuel cell companies skyward](https://longbridge.com/en/news/284609743.md)
- [Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation](https://longbridge.com/en/news/284938138.md)